Search results
Ultra runners face risk of kidney damage, finds study
Advnture via Yahoo News· 5 days agoThe other 10 suffered things like fatigue, hypothermia and gastric problems. To measure...
WSU professor gets new kidney after ‘40-year journey’
The Columbian· 3 days agoUpon receiving the call he would get a new kidney, Andrew Storfer had a hard time believing it. Four months earlier, the Washington State University professor had gotten the ...
Semaglutide significantly reduces risk of complications in patients with type 2 diabetes, study...
Medical Xpress· 3 days agoA pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients ...
Ozempic cuts kidney-disease risks, research finds
Market Watch· 3 days agoNovo Nordisk’s diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, ...
“Medical racism” in kidney care, how a calculation hurting black patients continued for decades
WFTV 9 Orlando· 4 days agoSome medical professionals and patients say two new federal policies are “righting a systemic wrong” and improving equity for kidney transplant patients. Since the 1990s, ...
After rejected kidney donation, S.I. mom issues plea: Help me save my daughter
Staten Island Advance· 4 days agoMelinda Torres didn’t hesitate to step up when her daughter, Alexis “Lexi” Tyson, needed a kidney....
Alien organs give hope of longer life
China Daily· 6 hours agoAlthough a living person can donate part of his or her liver without sacrificing his or her life, the operation in Anhui province is still a significant development because compatible liver ...
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
Reuters· 3 days ago, opens new tab Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 1 day agoIn addition, we presented data showing that atacicept leads to hematuria resolution in significantly more patients compared with placebo.
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KSAN - KLST San Angelo· 2 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European ...